News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Biotechnology Industry Organization (BIO) Urges Senate Committee on Finance Not to Limit Patients’ Access to Therapies
April 13, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) opposes the Chairman’s Mark to the Medicare Prescription Drug Price Negotiation Act of 2007 (S. 3) which is being considered by the Senate Committee on Finance today.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Government
American Medical Association Urges RFK Jr. to Maintain Preventive Task Force
July 28, 2025
·
2 min read
·
Tristan Manalac
Regulatory
Drug Pricing Just One Point of Confusion Over New FDA Vouchers
July 28, 2025
·
4 min read
·
Dan Samorodnitsky
Regulatory
Sarepta Fallout Continues With EU’s Negative Opinion of Elevidys in Ambulatory Patients
July 25, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
Sarepta’s Future Increasingly Uncertain as FDA Eyes New Study for Elevidys
July 25, 2025
·
4 min read
·
Tristan Manalac